CORE
CO
nnecting
RE
positories
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Research partnership
About
About
About us
Our mission
Team
Blog
FAQs
Contact us
Community governance
Governance
Advisory Board
Board of supporters
Research network
Innovations
Our research
Labs
Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours
Authors
Baggiolini M
Bonecchi R
+42 more
Bottazzi B
Burke F
Car BD
Clore GM
Colantonio L
Ebnet K
Forsythe JA
Gao JL
Gao W
Griffiths L
Grimshaw MJ
Grutkoski PS
Hockel M
Hosaka S
Howard OMZ
Kurihara T
Lu B
Mantovani A
Mantovani A
Mantovani A
Mattei S
Maxwell P
Naylor MS
Naylor MS
Negus RP
Negus RP
Negus RP
Quandt K
Schweickart VL
Sica A
Sica A
Signoret N
Takeya M
Turner L
Turner SJ
Van Coillie E
Vaupel P
Wang JM
Xu L
Yoong KF
Zella D
Zlotnik A
Publication date
9 May 2017
Publisher
Nature Publishing Group
Doi
View
on
PubMed
Abstract
To understand the chemokine network in a tissue, both chemokine and chemokine receptor expression should be studied. Human epithelial ovarian tumours express a range of chemokines but little is known about the expression and localisation of chemokine receptors. With the aim of understanding chemokine action in this cancer, we investigated receptors for CC–chemokines and their ligands in 25 biopsies of human ovarian cancer. CC–chemokine receptor mRNA was generally absent from solid tumours, the exception being CCR1 which was detected in samples from 75% of patients. CCR1 mRNA localised to macrophages and lymphocytes and there was a correlation between numbers of CD8+ and CCR1 expressing cells (P = 0.031). mRNA for 6 CC-chemokines was expressed in a majority of tumour samples. In a monocytic cell line in vitro, we found that CCR1 mRNA expression was increased 5-fold by hypoxia. We suggest that the CC-chemokine network in ovarian cancer is controlled at the level of CC-chemokine receptors and this may account for the phenotypes of infiltrating cells found in these tumours. The leukocyte infiltrate may contribute to tumour growth and spread by providing growth survival factors and matrix metalloproteases. Thus, CCR1 may be a novel therapeutic target in ovarian cancer. http://www.bjcancer.com © 2001 Cancer Research Campaignhttp://www.bjcancer.co
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Supporting member
Open Research Exeter
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:ore.exeter.ac.uk:10871/274...
Last time updated on 30/06/2017
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 01/04/2019